Technology startup, Infinion Biopharma Limited - set up by two NRI healthcare professionals - plans to invest Rs 100 crore towards developing innovative technologies in healthcare. It plans to set up a manufacturing and research facility in India.

The company looks to develop innovative technologies for key therapeutic areas of diabetes, women healthcare, drug delivery in pain and infection.

"We are currently scouting for suitable location in Ahmedabad or in Bengaluru. We primarily focus on developing new, economical and proprietary treatment options and technologies. We will raise the required funds from the promoters and other individual sources," said Vishal Jain, president & CEO, who is also one of the two promoters of the company.

The company is involved in developing a range of economical and proprietary treatment options for various indications including cancer, inflammatory disorders and diabetes. Infinion Biopharrma will patent the processes and products and plans to licence it out to drug makers. It also plans to enter the consumer segment by launching products.

The company is also developing localized, biodegradable drug-delivery technologies aimed at enhancing efficacy and reducing adverse side-effects with duration ranges of 7-10 days for surgical site infection and acute pain indications.

"Our strength is our ability to effectively combine various disciplines including immuno therapy, material science, biochemistry and physics," added Jain.

The first product from the company's stable will be rolled out in the next couple of years after the successful trials and required regulatory approvals in the Indian market. The first products will come in the area of diabetes and women healthcare.

Related Topics
comment COMMENT NOW